Protagonist Therapeutics Inc (PTGX)

Payables turnover

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Cost of revenue (ttm) US$ in thousands 1,712 2,544 3,371 3,300 3,312 2,736 2,762 2,784 2,785 3,348 2,495 1,652 819 0 0 0 0 0 0 2,774
Payables US$ in thousands
Payables turnover

December 31, 2024 calculation

Payables turnover = Cost of revenue (ttm) ÷ Payables
= $1,712K ÷ $—K
= —

Based on the provided data, the payables turnover ratio for Protagonist Therapeutics Inc is unavailable for the periods from March 31, 2020, to December 31, 2024.

The payables turnover ratio is a liquidity metric that indicates how efficiently a company manages its trade payables by measuring the number of times a company pays its suppliers during a specific period. A higher payables turnover ratio typically suggests that a company is paying off its suppliers more frequently, which can be a positive sign of strong liquidity management.

However, without the specific values of payables turnover for Protagonist Therapeutics Inc, it is challenging to assess the company's ability to manage its supplier payments effectively. It is recommended to monitor this ratio over time to evaluate changes in the company's liquidity management and supplier relationships.

It would be prudent for stakeholders and investors to seek additional information or financial data to gain a more comprehensive understanding of Protagonist Therapeutics Inc's payables turnover performance and its implications for the company's financial health.